Lucira Health (NASDAQ:LHDX) updated its first quarter 2021 earnings guidance on Tuesday. The company provided earnings per share guidance of – for the period. The company issued revenue guidance of $4 million-$4.50 million, compared to the consensus revenue estimate of $9.42 million.
A number of research analysts have commented on the company. Bank of America reiterated an underperform rating and issued a $9.00 price objective on shares of Lucira Health in a research report on Monday, April 19th. William Blair lowered Lucira Health from an outperform rating to a market perform rating in a research report on Tuesday. Finally, Lifesci Capital reiterated an outperform rating on shares of Lucira Health in a research report on Tuesday, March 2nd.
Shares of NASDAQ:LHDX traded down $0.37 during midday trading on Tuesday, hitting $5.61. The company had a trading volume of 520,233 shares, compared to its average volume of 654,596. Lucira Health has a 12 month low of $5.36 and a 12 month high of $37.99. The business has a fifty day moving average of $10.27.
In related news, major shareholder Epiq Capital Group, Llc purchased 3,461,764 shares of Lucira Health stock in a transaction dated Friday, February 5th. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $58,849,988.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Lucira Health Company Profile
Lucira Health, Inc, a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops testing platform that provides molecular testing services. The company offers LUCIRA COVID- 19 All- In- One Test Kit, that provides COVID- 19 result; and develops influenza A and B viruses test kits.
Further Reading: Market Indexes
Receive News & Ratings for Lucira Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucira Health and related companies with MarketBeat.com's FREE daily email newsletter.